Entirety Biomedical Closes $1.2 Million Seed Financing to Advance Absorbable Magnesium Implants for Orthopedic Fixation
DETROIT, Feb. 11, 2026 (GLOBE NEWSWIRE) — Entirety Biomedical, a Michigan-based medical device startup developing bioabsorbable implant systems with its proprietary Curasorb technology, today announced the closing of a $1.2 million Seed financing round to advance toward first-in-human clinical trials.
The round was led by NuFund Venture Group, with participation from Michigan Rise, Union Heritage, Revere Partners, Community Equity Partners, American Society of Plastic Surgeons, and Mass Medical Angels, among others.
Entirety is developing a portfolio of absorbable magnesium implant systems with its patented Curasorb alloy, designed to deliver the strength and handling characteristics surgeons expect from traditional titanium implants-then safely absorb once healing is complete. The company is initially focused on lower extremity and maxillofacial fixation systems, where absorbable implants have the potential to replace permanent metal hardware.
